PureTech Health plc announced that to oversee the LYT-100 development program in IPF, Paul Ford, M.D., Ph.D., has joined PureTech as SVP of Clinical Development. He has built and advanced programs from early to late-stage development at companies including Novartis, Galapagos and Galecto, and he has driven the recruitment and randomization of nearly 1,500 patients with IPF across several clinical studies.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
222.5 GBX | 0.00% | +0.45% | +14.57% |
May. 10 | EARNINGS AND TRADING: Asiamet Resources declares special dividend | AN |
May. 10 | EARNINGS AND TRADING: Asiamet Resources declares special dividend | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.57% | 762M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- PRTC Stock
- News PureTech Health plc
- PureTech Health plc Appoints Paul Ford as SVP of Clinical Development